American Diabetes Association (ADA)
2024 · updated 2024-01 · National professional society guideline
Comprehensive annual standards emphasising individualised, patient-centred glycaemic targets and organ protection.
Key recommendations
- •Metformin plus comprehensive lifestyle change as foundational therapy.
- •Use GLP-1 receptor agonists or SGLT2 inhibitors early in people with established ASCVD, heart failure or CKD, independent of HbA1c.
- •Prioritise weight management as a primary treatment goal.
- •Individualise HbA1c targets (often <7%) based on patient factors.
NICE (National Institute for Health and Care Excellence)
NG28 · updated 2022-06 · National clinical guideline
Stepwise, cost-effectiveness-informed pathway with structured education and defined HbA1c targets.
Key recommendations
- •Offer structured education (e.g. DESMOND) at or around diagnosis.
- •First-line metformin; add SGLT2 inhibitors where there is cardiovascular risk or heart failure.
- •Escalate therapy against agreed HbA1c thresholds (e.g. 48–58 mmol/mol).
- •Annual review including retinal, foot and renal assessment.
Research Society for the Study of Diabetes in India (RSSDI)
2022 · updated 2022-01 · National professional society guideline
Recommendations adapted to Indian phenotype, affordability and early-onset diabetes.
Key recommendations
- •Early combination therapy considered given aggressive phenotype.
- •Metformin first-line; cost and access weighed when selecting newer agents.
- •Emphasis on early screening due to younger age of onset.
- •Lifestyle intervention tailored to local diet and context.
Japan Diabetes Society (JDS)
2022-2023 · updated 2023-01 · National professional society guideline
Individualised targets with widespread early use of DPP-4 inhibitors reflecting local practice.
Key recommendations
- •Individualised HbA1c targets (often <7.0% NGSP for complication prevention).
- •DPP-4 inhibitors commonly used early in the pathway.
- •SGLT2 inhibitors and GLP-1 RAs for cardiorenal indications.
- •Diet and exercise emphasised as first steps.
Ministry of Health Malaysia
6th ed. · updated 2020-05 · National clinical guideline
National MOH CPG guiding metformin-first, target-based diabetes care in Malaysia.
Key recommendations
- •Metformin first-line with lifestyle intervention.
- •Individualised HbA1c targets.
- •Early combination therapy where indicated.
- •Structured complication screening.
Diabetes Association of Thailand
2023 · updated 2023-01 · National professional society guideline
Thai society guidance aligned with international standards and delivered under the UCS.
Key recommendations
- •Metformin-based first-line care.
- •Cardiorenal-protective agents where indicated.
- •Routine complication screening.
- •Lifestyle and self-management support.
AI synthesis strictly limited to the verified guideline data above — no recommendations are invented.